Table 1 Patient characteristics
Predictora | All patients (n = 454) | Patients without AF (n = 409) | Patients with AF (n = 45) | p V alue |
|---|---|---|---|---|
Demographic | ||||
Mean age, year | 65.4 ± 8.8 | 65.0 ± 8.9 | 68.6 ± 6.8 | 0.008 |
Male, n (%) | 369 (81.3) | 332 (81.2) | 37 (82.2) | 0.864 |
BMI, kg/m2 | 25.6 ± 4.1 | 25.7 ± 4.2 | 24.7 ± 3.3 | 0.116 |
Comorbidities | ||||
Paroxysmal AF, n (%) | 45 (9.9) | 38 (8.8) | 7 (15.5) | 0.182 |
CAD, n (%) | 56 (12.3) | 45 (11.0) | 11 (24.4) | 0.009 |
Prior AMI, n (%) | 15 (3.3) | 12 (2.9) | 3 (6.7) | 0.178 |
Hypertension, n (%) | 183 (40.3) | 161 (39.4) | 22 (48.9) | 0.216 |
Diabetes, n (%) | 58 (12.8) | 53 (13.0) | 5 (11.1) | 0.999 |
Dyslipidemia, n (%) | 71 (15.6) | 60 (14.7) | 11 (24.4) | 0.087 |
Current smokers, n (%) | 182 (40.1) | 164 (40.1) | 18 (40.0) | 0.990 |
PVD, n (%) | 115 (25.3) | 106 (25.9) | 9 (20.0) | 0.386 |
CVA, n (%) | 19 (4.2) | 16 (3.9) | 3 (6.7) | 0.421 |
Baseline biochemical data | ||||
Creatinine, mg/dL | 1.0 ± 0.5 | 1.0 ± 0.4 | 1.2 ± 1.1 | 0.287 |
Hb, g/dL | 13.8 ± 1.6 | 13.8 ± 1.5 | 13.6 ± 1.8 | 0.352 |
Baseline respiratory data | ||||
FEV1, % of predicted | 88.1 ± 21.9 | 88.2 ± 21.7 | 86.9 ± 24.1 | 0.716 |
PaO2, mmHg | 94.5 ± 21.9 | 94.3 ± 20.9 | 96.3 ± 29.2 | 0.558 |
Preoperative therapy | ||||
β-blockers, n (%) | 36 (7.9) | 29 (7.1) | 7 (15.6) | 0.046 |
Calcium antagonists, n (%) | 58 (12.8) | 51 (12.5) | 7 (15.6) | 0.556 |
ACE-Inhibitors, n (%) | 67 (14.8) | 59 (14.4) | 8 (17.8) | 0.547 |
ARBs, n (%) | 33 (7.3) | 29 (7.1) | 4 (8.9) | 0.659 |
Statins, n (%) | 45 (9.9) | 39 (9.5) | 6 (13.3) | 0.429 |
Neoadjuvant chemotherapy, n (%) | 30 (6.6) | 28 (6.8) | 2 (4.4) | 0.756 |